Janux Therapeutics (JANX) Cash from Financing Activities (2020 - 2026)

Janux Therapeutics (JANX) has reported Cash from Financing Activities for 7 consecutive years, with $3.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Cash from Financing Activities rose 539.89% year-over-year to $3.5 million; the TTM figure through Mar 2026 stood at $7.9 million (down 97.97% YoY), while the FY2025 annual figure was $4.9 million, down 99.31% from the prior year.
• Cash from Financing Activities rose to $3.5 million in Q1 2026 per JANX's latest filing, from $2.9 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $386.6 million in Q4 2024 and bottomed at $1000.0 in Q1 2022.
• Historically, Cash from Financing Activities has averaged $48.9 million across 5 years, with a median of $1.3 million in 2023.
• Annual changes were most pronounced in 2022 — Cash from Financing Activities slumped 100.0% — and 2023, when it soared 157900.0%.
• Janux Therapeutics' Cash from Financing Activities stood at $191000.0 in 2022, then soared by 335.08% to $831000.0 in 2023, then surged by 46428.28% to $386.6 million in 2024, then tumbled by 99.24% to $2.9 million in 2025, then rose by 20.41% to $3.5 million in 2026.
• Business Quant data shows JANX's Cash from Financing Activities at $3.5 million in Q1 2026, $2.9 million in Q4 2025, and $493000.0 in Q3 2025.